Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT

M. Sever, J. Drozd-Sokolowska, L. Gras, L. Koster, F. Folber, S. Mielke, R. Fenk, G. Basak, J. Apperley, J. Byrne, A. Rambaldi, M. Ringhoffer, M. Eder, M. Trneny, D. Blaise, S. Lenhoff, C. Isaksson, J. Passweg, A. Partanen, I. Sakellari, S....

. 2025 ; 60 (2) : 211-219. [pub] 20241112

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010103

Autologous hematopoietic cell transplants (auto-HCTs) remain the standard of care for transplant-eligible MM patients. The general practice has been to undergo upfront apheresis following induction to collect sufficient number of CD34+ cells to facilitate two auto-HCTs. However, 5-30% of MM patients do not initially mobilise a sufficient number of hematopoietic stem cells and are classified as poor mobilizers (PM). We compared the baseline characteristics and outcomes of 61 PMs and 816 non-PM patients who underwent a second auto-HCT and who were enrolled in the non-interventional CALM study (NCT01362972). Only patients who collected CD34+ prior to auto-HCT1 were included. Auto-HCT2 comprised both tandem and salvage transplants. PMs were re-mobilized with plerixafor (n = 24, 39.3%) or non-plerixafor-based regimens (n = 37, 60.7%). There were no significant differences in engraftment, progression-free survival (PFS) or overall survival (OS) after the second auto-HCT between PM and non-PM patients. There was a trend to shorter PFS in PM patients undergoing salvage auto-HCT (median 9.6 vs. 12.9 months; p = 0.08) but no significant difference in OS. The median OS was 41.1 months for PM and 41.2 months for non-PM patients (p = 0.86). These data suggest that salvage mobilization is effective and does not affect overall outcomes after a second auto-HCT.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010103
003      
CZ-PrNML
005      
20250429134519.0
007      
ta
008      
250415s2025 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1038/s41409-024-02460-7 $2 doi
035    __
$a (PubMed)39533015
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Sever, Matjaz $u University Medical Centre, Ljubljana and Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
245    10
$a Satisfactory outcomes following a second autologous hematopoietic cell transplantation for multiple myeloma in poor stem cell mobilizers: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT / $c M. Sever, J. Drozd-Sokolowska, L. Gras, L. Koster, F. Folber, S. Mielke, R. Fenk, G. Basak, J. Apperley, J. Byrne, A. Rambaldi, M. Ringhoffer, M. Eder, M. Trneny, D. Blaise, S. Lenhoff, C. Isaksson, J. Passweg, A. Partanen, I. Sakellari, S. Schönland, C. Morris, M. Beksac, K. Raj, PJ. Hayden, DP. McLornan
520    9_
$a Autologous hematopoietic cell transplants (auto-HCTs) remain the standard of care for transplant-eligible MM patients. The general practice has been to undergo upfront apheresis following induction to collect sufficient number of CD34+ cells to facilitate two auto-HCTs. However, 5-30% of MM patients do not initially mobilise a sufficient number of hematopoietic stem cells and are classified as poor mobilizers (PM). We compared the baseline characteristics and outcomes of 61 PMs and 816 non-PM patients who underwent a second auto-HCT and who were enrolled in the non-interventional CALM study (NCT01362972). Only patients who collected CD34+ prior to auto-HCT1 were included. Auto-HCT2 comprised both tandem and salvage transplants. PMs were re-mobilized with plerixafor (n = 24, 39.3%) or non-plerixafor-based regimens (n = 37, 60.7%). There were no significant differences in engraftment, progression-free survival (PFS) or overall survival (OS) after the second auto-HCT between PM and non-PM patients. There was a trend to shorter PFS in PM patients undergoing salvage auto-HCT (median 9.6 vs. 12.9 months; p = 0.08) but no significant difference in OS. The median OS was 41.1 months for PM and 41.2 months for non-PM patients (p = 0.86). These data suggest that salvage mobilization is effective and does not affect overall outcomes after a second auto-HCT.
650    _2
$a lidé $7 D006801
650    12
$a transplantace hematopoetických kmenových buněk $x metody $7 D018380
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé středního věku $7 D008875
650    _2
$a retrospektivní studie $7 D012189
650    12
$a mnohočetný myelom $x terapie $x mortalita $7 D009101
650    12
$a mobilizace hematopoetických kmenových buněk $x metody $7 D019650
650    12
$a autologní transplantace $x metody $7 D014182
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Drozd-Sokolowska, Joanna $u University Clinical Centre, Medical University of Warsaw, Warsaw, Poland. joanna.drozd-sokolowska@wum.edu.pl $1 https://orcid.org/0000000245626264
700    1_
$a Gras, Luuk $u EBMT Leiden Statistical Unit, Leiden, the Netherlands
700    1_
$a Koster, Linda $u EBMT Leiden Study Unit, Leiden, the Netherlands
700    1_
$a Folber, Frantisek $u University Hospital Brno, Brno, Czech Republic $1 https://orcid.org/000000017034769X
700    1_
$a Mielke, Stephan $u Karolinska University Hospital, Stockholm, Sweden
700    1_
$a Fenk, Roland $u Heinrich Heine Universitaet, Duesseldorf, Germany
700    1_
$a Basak, Grzegorz $u University Clinical Centre, Medical University of Warsaw, Warsaw, Poland $1 https://orcid.org/0000000338588180
700    1_
$a Apperley, Jane $u Imperial College Hammersmith, London, UK $1 https://orcid.org/0000000217101794
700    1_
$a Byrne, Jennifer $u Nottingham City Hospital, Nottingham, UK
700    1_
$a Rambaldi, Alessandro $u ASST Papa Giovanni XXIII, Bergamo, Italy $1 https://orcid.org/0000000237397502 $7 xx0317376
700    1_
$a Ringhoffer, Mark $u Klinikum Karlsruhe gGmbH, Karlsruhe, Germany
700    1_
$a Eder, Matthias $u Hannover Medical School, Hannover, Germany
700    1_
$a Trneny, Marek $u Charles University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000269526073 $7 nlk20000083659
700    1_
$a Blaise, Didier $u Programme de Transplantation&Therapie Cellulaire, Marseille, France $1 https://orcid.org/0000000256849447
700    1_
$a Lenhoff, Stig $u Skanes University Hospital, Lund, Sweden
700    1_
$a Isaksson, Cecilia $u Umea University Hospital, Umeå, Sweden
700    1_
$a Passweg, Jakob $u University Hospital I Basel, Basel, Switzerland $1 https://orcid.org/0000000170923351
700    1_
$a Partanen, Anu $u Kuopio University Hospital, Kuopio, Finland $1 https://orcid.org/0000000256342582
700    1_
$a Sakellari, Ioanna $u George Papanicolaou General Hospital, Thessaloniki, Greece
700    1_
$a Schönland, Stefan $u Medizinische Klinik u. Poliklinik V, University of Heidelberg, Heidelberg, Germany $1 https://orcid.org/0000000248535579
700    1_
$a Morris, Curly $u Belfast City Hospital, Belfast, Northern Ireland
700    1_
$a Beksac, Meral $u Faculty of Medicine, Liv Hospital, Ankara, Turkey
700    1_
$a Raj, Kavita $u University College London Hospitals NHS Trust, London, UK $1 https://orcid.org/000000028258354X
700    1_
$a Hayden, Patrick J $u Department of Haematology, Trinity College Dublin, St. James's Hospital, Dublin, Ireland $1 https://orcid.org/0000000313744503
700    1_
$a McLornan, Donal P $u University College London Hospitals NHS Trust, London, UK $1 https://orcid.org/000000031224091X
773    0_
$w MED00000834 $t Bone marrow transplantation $x 1476-5365 $g Roč. 60, č. 2 (2025), s. 211-219
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39533015 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134515 $b ABA008
999    __
$a ok $b bmc $g 2311461 $s 1247184
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 60 $c 2 $d 211-219 $e 20241112 $i 1476-5365 $m Bone marrow transplantation $n Bone Marrow Transplant $x MED00000834
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace